ENHERTU (Daiichi Sankyo, Inc.)
(https://enhertu.com) 📸 Data Snapshot: June 20, 2026
Trust & Proof — The Lens
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Trust & Proof
Verifiable evidence vs. Trust Theatre.
19
Impact Weight: 20 / 100
95% Reputation
Trust theatre is non-existent as the site avoids the typical ‘customer testimonial’ trap found in high-BS sites. Instead of review_count, it relies on clinical trial results and provides direct proof_links to ‘Prescribing Information’ and ‘Medication Guides.’ The only reason for a 1-point score is the use of the marketing superlative ‘breakthrough’ without an immediate peer-reviewed citation in the hero section, though it is footnoted later.
Proof density is at the maximum possible level for a commercial medical site. Every major efficacy claim is linked to clinical studies that measured response duration and patient counts. The site provides specific technical specifications (100 mg lyophilized powder) and administration routes (IV infusion), leaving no room for vague assertions typical of low-substance websites.
Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.
🛡️ Trust Signals — reviews, proof links, trust-theatre check
0Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /en/ | 0 | 0 |
| /en/breast/ | 0 | 0 |
| /en/her2-low-breast/ | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage schema
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/",
"audience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"mainEntity": {
"@type": "Drug",
"name": "ENHERTU",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
"legalStatus": "FDA Approved",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"isProprietary": "True",
"isAvailableGenerically": "False",
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"dosageForm": "Injection for Intravenous Use",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"administrationRoute": "IV infusion",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"foodWarning": "",
"alcoholWarning": "",
"pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"interactingDrug": ""
},
"about": [
{
"@type": "MedicalCondition",
"name": "HER2+ Metastatic Breast Cancer",
"alternateName": "HER2+ mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2+ Advanced Stomach Cancer",
"alternateName": "HER2+ aGC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Stomach"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2 Mutant Metastatic Lung Cancer",
"alternateName": "HER2 Mutant NSCLC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Lung"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2-low Metastatic Breast Cancer",
"alternateName": "HER2-low mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
}
]
}
/en/
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/",
"audience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"mainEntity": {
"@type": "Drug",
"name": "ENHERTU",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
"legalStatus": "FDA Approved",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"isProprietary": "True",
"isAvailableGenerically": "False",
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"dosageForm": "Injection for Intravenous Use",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"administrationRoute": "IV infusion",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"foodWarning": "",
"alcoholWarning": "",
"pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"interactingDrug": ""
},
"about": [
{
"@type": "MedicalCondition",
"name": "HER2+ Metastatic Breast Cancer",
"alternateName": "HER2+ mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2+ Advanced Stomach Cancer",
"alternateName": "HER2+ aGC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Stomach"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2 Mutant Metastatic Lung Cancer",
"alternateName": "HER2 Mutant NSCLC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Lung"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2-low Metastatic Breast Cancer",
"alternateName": "HER2-low mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
}
]
}
/en/breast/ — no schema detected (entity gap)
/en/her2-low-breast/
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/en/her2-low-breast",
"description": "Learn about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results and safety data. See the full Important Safety Information, Prescribing Information, including Boxed WARNINGS, and Medication Guide for more information.",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"medicalAudience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us/home",
"logo": "https://enhertu.com/-/media/enhertu_patient/images/footer/daiichi-sankyo-astra-zeneca-logo.ashx",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"specialty": [
"https://health-lifesci.schema.org/Oncologic",
"https://schema.org/Oncologic"
],
"mainEntity": {
"@id": "https://enhertu.com/en/her2-low-breast#Drug",
"@type": "Drug",
"name": "ENHERTU",
"brand": {
"@type": "Brand",
"name": "ENHERTU",
"logo": "https://enhertu.com/-/media/enhertu_patient/images/header/enhertu-logo.ashx",
"description": "Find valuable information about ENHERTU® (fam-trastuzumab deruztecan-nxki), including clinical trial results, safety information, downloadable resources, and more. See Full Safety, Boxed WARNINGS, & Medication Guide for more information.",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan"
},
"isProprietary": "True",
"isAvailableGenerically": "False",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"administrationRoute": "IV infusion",
"alcoholWarning": "N/A",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:\n o have lung or breathing problems\n o have signs or symptoms of an infection\n o have or have had any heart problems\n o are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"dosageForm": "Injection for intravenous use",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"foodWarning": "N/A",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. \n\n1. ENHERTU is made up of an antibody with the chemotherapy attached \n2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell \n3. ENHERTU enters the cancer cell and the chemotherapy is released \n4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby \n\nAlthough ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://www.daiichisankyo.us",
"logo": "https://daiichisankyo.us/documents/d/dsi/logo",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"pregnancyWarning": "• Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. \n o If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. \n o Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose. \n o Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.",
"interactingDrug": "N/A",
"doseSchedule": {
"@type": "DoseSchedule",
"doseUnit": "mg/kg",
"doseValue": "5.4",
"frequency": "Once every 3 weeks",
"targetPopulation": "Adults"
}
},
"about": {
"@type": "MedicalCondition",
"name": "HER2-low and HR+, HER2-ultralow Metastatic Breast Cancer",
"alternateName": "HER2-low and HR+, HER2-ultralow mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"possibleTreatment": {
"@id": "https://enhertu.com/en/her2-low-breast#Drug"
}
}
}
Explore the other reputation pillars for ENHERTU (Daiichi Sankyo, Inc.)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from ENHERTU (Daiichi Sankyo, Inc.), captured on June 20, 2026, to show how machine logic reads Trust & Proof signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to ENHERTU (Daiichi Sankyo, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://enhertu.com to view the most current version of its content and see directly what this company is about and what it offers.